Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages
- PMID: 12842429
- DOI: 10.1016/s1525-0016(03)00140-0
Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages
Abstract
The phenomenon of RNA interference mediated by small interfering RNAs (siRNAs) is a potent gene-silencing mechanism. A number of recent studies demonstrated inhibition of HIV-1 replication in cultured cells using this approach. To make further progress and harness this technology for HIV-1 gene therapy in a stem cell setting, in vivo studies using primary hematopoietic cells are needed. Using an HIV-based lentiviral vector we introduced an anti-Rev siRNA construct into CD34(+) hematopoietic progenitor cells. The siRNA-transduced progenitor cells were allowed to mature into macrophages in vitro and T cells in vivo in SCID-hu mouse thy/liv grafts. Phenotypically normal T cells and macrophages displaying characteristic surface markers were obtained. In vitro HIV-1 challenge of the siRNA-expressing macrophages and T cells with macrophage-tropic and T-cell-tropic HIV-1, respectively, showed marked viral resistance. These experiments demonstrate the utility of siRNAs delivered into hematopoietic stem cells via lentiviral vectors for future in vivo applications.
Similar articles
-
RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.Mol Ther. 2002 Dec;6(6):770-82. doi: 10.1006/mthe.2002.0800. Mol Ther. 2002. PMID: 12498773
-
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells.Mol Ther. 2007 Jun;15(6):1182-8. doi: 10.1038/sj.mt.6300157. Epub 2007 Apr 3. Mol Ther. 2007. PMID: 17406343
-
Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.Mol Ther. 2000 Mar;1(3):244-54. doi: 10.1006/mthe.2000.0038. Mol Ther. 2000. PMID: 10933940
-
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review.
-
Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906. Curr HIV Res. 2004. PMID: 15078182 Review.
Cited by
-
An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review.Pharmacol Rep. 2021 Oct;73(5):1265-1272. doi: 10.1007/s43440-021-00257-9. Epub 2021 Apr 11. Pharmacol Rep. 2021. PMID: 33840054 Free PMC article. Review.
-
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.Acta Naturae. 2013 Apr;5(2):7-18. Acta Naturae. 2013. PMID: 23819033 Free PMC article.
-
RNA interference: a potent tool for gene-specific therapeutics.Am J Transplant. 2004 Aug;4(8):1227-36. doi: 10.1111/j.1600-6143.2004.00530.x. Am J Transplant. 2004. PMID: 15268723 Free PMC article. Review.
-
Humanized mouse models of HIV infection.AIDS Rev. 2011 Jul-Sep;13(3):135-48. AIDS Rev. 2011. PMID: 21799532 Free PMC article. Review.
-
RNAi therapy for HIV infection: principles and practicalities.BioDrugs. 2007;21(1):17-22. doi: 10.2165/00063030-200721010-00003. BioDrugs. 2007. PMID: 17263586 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical